Incidence of gastroduodenal ulcers - week 12 Celecoxib - Phase III RA and OA UGI Safety Trials

* Significantly different from all other treatments; P < 0.001

*

0

5

10

15

20

25

30

% Patients with Ulcer

Placebo

(n=205)

Celecoxib

50 mg BID

(n=164)

Celecoxib

100 mg BID

(n=303)

Celecoxib

200 mg BID

(n=295)

Celecoxib

400 mg BID

(n=130)

Naproxen

500 mg BID

(n=283)

Data on File: Searle (Studies 021 & 022)

Previous slide

Next slide

Back to first slide

View graphic version